Management of Bilateral Basal Ground‑Glass Opacities

Initial Clinical Assessment

• Obtain a detailed medication history, focusing on recent initiation of molecular‑targeted agents, immune‑checkpoint inhibitors, or chronic corticosteroids, because drug‑related pneumonitis frequently presents with bilateral ground‑glass opacities. 1
• Identify immunosuppressed individuals (e.g., those receiving chronic immunosuppression) as they are at high risk for Pneumocystis jirovecii pneumonia, which characteristically produces bilateral ground‑glass opacities. 1
• Ask about recent COVID‑19 exposure or infection, since post‑COVID residual changes can persist as bilateral ground‑glass opacities. 3
• Collect a comprehensive exposure history (occupational, environmental, hobby‑related) to evaluate for hypersensitivity pneumonitis, a condition that may manifest with bilateral ground‑glass opacities and centrilobular nodules. 2

Early Diagnostic Work‑up (First 48–72 h)

• Start empiric broad‑spectrum antibiotics covering typical and atypical respiratory pathogens while awaiting microbiologic results; lack of clinical improvement within 48–72 h strongly suggests a non‑infectious inflammatory process and should trigger escalation of the work‑up. 2
• Obtain microbiologic specimens—including sputum and blood cultures, a respiratory viral panel, and Pneumocystis testing in immunosuppressed patients—to rule out infectious etiologies. 1

Role of Bronchoscopy and BAL

• Perform bronchoscopy with broncho‑alveolar lavage (BAL) when there is no response to empiric antibiotics or when high‑resolution CT (HRCT) shows an inflammatory rather than consolidative pattern. 1
• BAL analysis should include cultures for bacteria, fungi, mycobacteria, and Pneumocystis; cell‑differential assessment (lymphocytosis → hypersensitivity pneumonitis or organizing pneumonia; eosinophilia → eosinophilic pneumonia; neutrophilia → drug‑related pneumonitis or infection); and cytology to exclude malignancy or diffuse alveolar hemorrhage. 1
• Transbronchial biopsy during bronchoscopy can confirm organizing pneumonia and help exclude alternative diagnoses, offering a favorable risk‑benefit profile. 2

HRCT Pattern Recognition

Sources: 1, 4, 2, 5, 3

Treatment Strategies

Drug‑Related Pneumonitis

• Immediately discontinue the suspected offending medication. 1
• Initiate oral prednisone 0.5–1 mg/kg/day with a gradual taper over weeks to months for symptomatic patients. 1
• Expect clinical and radiographic improvement within days to weeks; lack of response should prompt reconsideration of the diagnosis. 1

Cryptogenic Organizing Pneumonia

• Start oral prednisolone; most patients experience rapid symptomatic and radiologic improvement within days to weeks. 4
• Anticipate a response rate >80%; however, relapse is common and may require a prolonged taper (6–12 months). 4
• Prognosis is excellent when appropriate corticosteroid therapy is administered. 4

Hypersensitivity Pneumonitis

• Implement strict avoidance of the inciting antigen combined with a course of corticosteroids to achieve optimal clinical and imaging outcomes. 2
• Overall prognosis is favorable when antigen removal and steroids are employed. 2

Desquamative Interstitial Pneumonia

• Enforce smoking cessation as a mandatory intervention. 5
• Treat with corticosteroids; 10‑year survival is approximately 70%, markedly better than that of usual interstitial pneumonia. 5

Critical Pitfalls to Avoid

• Do not extend empiric antibiotic therapy beyond 48–72 h without evidence of clinical improvement, as this delays necessary anti‑inflammatory treatment. 2
• Avoid initiating anti‑tuberculosis therapy solely on the basis of radiographic opacities; this can cause unnecessary toxicity and postpone correct diagnosis. 2
• Never overlook a detailed exposure history, which is essential for diagnosing hypersensitivity pneumonitis and improving diagnostic accuracy. 2
• Do not label post‑COVID residual abnormalities as “interstitial lung abnormality” (ILA); per Fleischner Society guidelines, ILA is reserved for incidental or unexpected findings. 3
• Re‑challenge with a suspected offending drug should be avoided because it can exacerbate drug‑related pneumonitis. 1

Prognosis by Etiology

• Cryptogenic organizing pneumonia: >80% achieve response to corticosteroids with excellent long‑term outcomes. 4
• Hypersensitivity pneumonitis: Generally favorable when the antigen is removed and steroids are given. 2
• Drug‑related pneumonitis: Variable; most patients improve after drug cessation and corticosteroid therapy. 1
• Desquamative interstitial pneumonia: Approximately 70% survive at 10 years with smoking cessation and steroid treatment. 5
• Acute interstitial pneumonia: Carries a high mortality risk (≥50%) when this pattern is present. 2